Physicians and Pharmacists as Fine Artists

Ritschel, W. A.

doi:10.1016/s1086-5802(16)31112-3

Cited by 3 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, patients with an albumin level <3 g/dL would be expected to exhibit a higher free faction of antibiotic and a higher CL because these two parameters are directly related (renal CL = unbound drug × eGFR) [8]. Indeed, a difference in GFR was observed between subgroups because this rate increased in patients with albumin levels > 3 g/dL.…”

Section: Discussionmentioning

confidence: 99%

Pharmacokinetics of piperacillin/tazobactam in cancer patients with hematological malignancies and febrile neutropenia after chemotherapy

Álvarez

Cuervo

Garzón³

et al. 2013

BMC Pharmacol Toxicol

View full text Add to dashboard Cite

IntroductionPatients with febrile neutropenia (FN) exhibit changes in extracellular fluid that may alter the plasma concentrations of beta-lactams and result in therapeutic failure or toxicity. We evaluated the pharmacokinetics of piperacillin/tazobactam in patients with hematological malignancies and FN after receiving chemotherapy at a primary public cancer center.MethodsThis was an open, nonrandomized, observational, descriptive, and prospective study. Samples from 15 patients with hematological malignancies and FN were evaluated after the administration of chemotherapy. Five blood samples were taken from each patient when the antibiotic level was at steady-state 10, 60, 120, 180, and 350 min after each dose. Antibiotic concentrations were measured using gel diffusion with Bacillus subtilis. All study participants provided written informed consent.ResultsWe investigated the pharmacokinetics of piperacillin in 14 patients between the ages of 18 years and 59 years and with a mean absolute neutrophil count of 208 cells per mm3 (standard deviation (SD) ± 603.2). The following pharmacokinetic measurements were obtained: maximum concentration, 94.1–1133 mg/L; minimum concentration, 0.47–37.65 mg/L; volume of distribution, 0.08–0.65 L/kg (mean, 0.34 L/kg); drug clearance (CL), 4.42–27.25 L/h (mean, 9.93 L/h); half-life (t1/2), 0.55–2.65 h (mean, 1.38 h); and area under the curve, 115.12–827.16 mg · h/L.ConclusionPatients with FN after receiving chemotherapy exhibited significant variations in the pharmacokinetic parameters of piperacillin compared with healthy individuals; specifically, FN patients demonstrated an increase in t1/2 and decreased CL.

show abstract

Section: Discussionmentioning

confidence: 99%

Pharmacokinetics of piperacillin/tazobactam in cancer patients with hematological malignancies and febrile neutropenia after chemotherapy

Álvarez

Cuervo

Garzón³

et al. 2013

BMC Pharmacol Toxicol

View full text Add to dashboard Cite

show abstract

“…The CYP3A subfamily encompasses up to 40% of the total cytochrome P450 content in the adult liver and small intestine (22). CYP3A7 is the fetal form of CYP3A and accounts for 30% to 50% of total hepatic cytochrome P450.…”

Section: Does Cisapride Cause Serious Dose‐related Adverse Effects?mentioning

confidence: 99%